The acquired immunodeficiency syndrome (AIDS) caused by HIV-1 is the leading cause of death in Africa and the fourth leading cause of death worldwide. This IPCAVD is developing HIV/AIDS vaccines that use DNA for priming and MVA for boosting (DNA/MVA vaccine) as well as a simpler an ultimately easier to deploy form of these vaccines, the use of MVA for both priming and boosting (MVA/MVA vaccine). Both the DNA and MVA vaccines use single vectors to express virus like particles (VLP). This IPCAVD seeks to build GM-CSF, an adjuvant, into these products for expression in cis. In preclinical studies, co-expression of GMCSF has substantially enhanced protection. A central hypothesis for the IPCAVD is that GM-CSF improves protection by enhancing the mucosal presence of elicited T cell and Ab responses. Clade C HIV-1 which is endemic in southern Africa and parts of Asia accounts for about one half of the infections worldwide and >90% of the cases in India, a country with a rapidly spreading infection that has surpassed South Africa in its total number of cases. The vaccine development effort of this IPCAVD is focused on developing a clade C vaccine for India. This administrative core has five specific aims: ? Provide overall co-ordination for the Program ? Provide data management and statistical support ? Provide logistical support for intellectual property filings and negotiations ? Assist with publications ? Maintain budgets and fiscal oversight Dr. Harriet Robinson, the Program Director, will lead the Administrative core. She has demonstrated experience in leading IPCAVD programs and moving concepts from the bench to early phase clinical trials through the HVTN.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI074073-04
Application #
8132549
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
4
Fiscal Year
2010
Total Cost
$506,604
Indirect Cost
Name
Geovax, Inc.
Department
Type
DUNS #
148374205
City
Smyrna
State
GA
Country
United States
Zip Code
30080
Chamcha, Venkateswarlu; Kannanganat, Sunil; Gangadhara, Sailaja et al. (2016) Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Open Forum Infect Dis 3:ofw034
Kannanganat, Sunil; Wyatt, Linda S; Gangadhara, Sailaja et al. (2016) High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5?-Restrictive Macaques. J Immunol 197:3586-3596
Kannanganant, Sunil; Gangadhara, Salaija; Lai, Lilin et al. (2014) Local control of repeated-dose rectal challenges in DNA/MVA-vaccinated macaques protected against a first series of simian immunodeficiency virus challenges. J Virol 88:5864-9
Robinson, Harriet L (2013) Non-neutralizing antibodies in prevention of HIV infection. Expert Opin Biol Ther 13:197-207
Nandakumar, Subhadra; Kannanganat, Sunil; Dobos, Karen M et al. (2013) O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection. PLoS Pathog 9:e1003705
Hellerstein, Michael; Xu, Yongxian; Marino, Tracie et al. (2012) Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum Vaccin Immunother 8:1654-8
Lai, Lilin; Kwa, Suefen; Kozlowski, Pamela A et al. (2011) Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 204:164-73
Pillai, Vinod Bhaskara; Hellerstein, Michael; Yu, Tianwei et al. (2008) Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26:1136-41